肺心病患者治疗前后可溶性白细胞介素-2受体和肿瘤坏死因子检测的临床意义  

Clinical Significance of Detecing SIL-2R and TNF in Pulmonary Heart Disease

作　　者：周福英[1] 何浩明[1] 田小平[1] 徐凤英[1] 苏彩女[1] 

机构地区：[1]江苏省连云港市第一人民医院呼吸科

出　　处：《包头医学院学报》1998年第3期24-25,共2页Journal of Baotou Medical College

摘　　要：为探讨ＳＩＬ－２Ｒ和ＴＮＦ在肺心病患者中含量的变化及意义，采用双抗体夹心酶联免疫和放免法检测３２例肺心病患者血清中ＳＩＬ－２Ｒ和ＴＮＦ水平。结果显示：各期肺心病患者ＳＩＬ－２Ｒ急性期为１６２０．４±３０５．６ｕ／ｍｌ，缓解期为９２８．５±２８４．７ｕ／ｍｌ，恢复期为３０２．５±１５５．６ｕ／ｍｌ；ＴＮＦ急性期为１．０９±０．３３ｎｇ／ｍｌ，缓解期为０．８１±０．２１ｎｇ／ｍｌ，恢复期为０．６９±０．１２１ｎｇ／ｍｌ。To study the clinical significance of the alteration of the level of serum SIL-2R and TNF in pulmonary heart disease,double antibody sandwich enzyme-link immunosorbent assay was used to detect the level of receptor interleukin-2(SIL-2R)and tumour necosis factors(TNF)in the serum of 32 patients with pulmonary heart disease.The results show that the level of serum SIL-2R is 1620.4±305 6u/ml in acute attack stage,928.5±284.7u/ml in remissive stage and 302.5±155.6u/ml in restoration stage,repectively,and that the level of serum TNF is 1.09±0.33ng/ml in the attack stage,0.81±0.2ng/ml in the remissive stage and 0.69±0.12ng/ml in the restoration stage,respectively.It is suggested that detecing of the level of serum SIL-2R and TNF plays an important part in clinical observation of pulmonary heart disease.

关 键 词：肺心病 SIL-2R 肿瘤坏死因子 

分 类 号：R541.505[医药卫生—心血管疾病]